ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2015. The company specializes in developing and commercializing innovative, needle-free treatments for severe allergic reactions, particularly through its flagship product, neffy. Neffy is the first FDA-approved needle-free epinephrine nasal spray, designed as a rescue medication for individuals experiencing Type I severe allergic reactions, including anaphylaxis. This product offers a low-dose, intranasal alternative to traditional needle-based injections, enhancing ease of use and reducing needle-related concerns.
In addition to neffy, ARS Pharmaceuticals is working on pipeline products like ARS-2, an intranasal epinephrine formulation aimed at treating acute flares of urticaria (hives). The company serves healthcare professionals, patients, and caregivers across the United States, providing patient-friendly treatments and support programs to improve access to its therapies. With approximately 160 employees, ARS Pharmaceuticals is publicly traded on NASDAQ under the ticker SPRY.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2015. The company specializes in developing and commercializing innovative, needle-free treatments for severe allergic reactions, particularly through its flagship product, neffy. Neffy is the first FDA-approved needle-free epinephrine nasal spray, designed as a rescue medication for individuals experiencing Type I severe allergic reactions, including anaphylaxis. This product offers a low-dose, intranasal alternative to traditional needle-based injections, enhancing ease of use and reducing needle-related concerns.
In addition to neffy, ARS Pharmaceuticals is working on pipeline products like ARS-2, an intranasal epinephrine formulation aimed at treating acute flares of urticaria (hives). The company serves healthcare professionals, patients, and caregivers across the United States, providing patient-friendly treatments and support programs to improve access to its therapies. With approximately 160 employees, ARS Pharmaceuticals is publicly traded on NASDAQ under the ticker SPRY.
